A Phase I/II Trial Testing Nelfinavir, an Inhibitor of Akt Signaling, in Combination With Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.

Trial Profile

A Phase I/II Trial Testing Nelfinavir, an Inhibitor of Akt Signaling, in Combination With Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2013

At a glance

  • Drugs Nelfinavir (Primary) ; Capecitabine
  • Indications Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 May 2013 Planned number of patients changed from 55 to 61 as reported by European Clinical Trials Database.
    • 04 May 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 07 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top